Manageable Toxicity, Promising Antitumor Activity With Pembrolizumab for Gastric Cancer

Share this content:
Pembrolizumab may have a manageable toxicity profile and promising antitumor activity in patients with recurrent or metastatic PD-L1-positive gastric cancer.
Pembrolizumab may have a manageable toxicity profile and promising antitumor activity in patients with recurrent or metastatic PD-L1-positive gastric cancer.

Pembrolizumab may have a manageable toxicity profile and promising antitumor activity in patients with recurrent or metastatic PD-L1-positive gastric cancer, according to a study published in The Lancet Oncology.1

Researchers led by Kei Muro, MD, of the Aichi Cancer Center Hospital in Japan conducted a multicenter, open-label, phase 1b trial of 39 patients enrolled across 13 cancer research centers in the United States, Israel, Japan, South Korea, and Taiwan.

Patients had PD-L1-positive recurrent or metastatic adenocarcinoma of the stomach or gastro-esophageal junction and received intravenous pembrolizumab once every 2 weeks for 24 months or until progression or unacceptable toxic effects occurred. Response to treatment was assessed every 8 weeks in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) guidelines version 1.1.

Among the observed patients, 36 were evaluable for response by central assessment, and 8 of those patients were judged to have had an overall response at central review. All responses were found to be partial.

RELATED: Adding Gastrectomy to Chemo Not Effective for Advanced Gastric Cancer

All 39 patients were included in the safety analyses, and 5 patients were found to have a total of 6 grade 3 or 4 treatment-related adverse events that included grade 3 fatigue, hypothyroidism, and peripheral sensory neuropathy. There were no treatment-related deaths.

Reference

  1. Muro K, Chung HC, Shankaran V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial [published online ahead of print May 3, 2016]. The Lancet Oncol. doi: 10.1016/S1470-2045(16)00175-3.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters